Human Trials

BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) plus radiation has failed to meet its primary endpoint of overall survival (OS) in phase 3 brain cancer trial.

Merck announces results from phase 2 trial of V114 in infants

Merck, known as MSD outside of the US and Canada, announced results from a Phase 2 trial (NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114.

Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial

Merck announced the presentation of results of a phase 3 trial evaluating the efficacy and safety of BELSOMRA (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer’s disease dementia.

Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

Xencor has dosed the first patient in a phase 1 clinical trial that will evaluate its bispecific antibody XmAb23104 for the treatment of advanced solid tumors.

AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial

AstraZeneca announced that its blood cancer drug Calquence (acalabrutinib) has met its primary endpoint at interim analysis in the phase III Ascend (ACE-CL-309) trial.

PharmaCyte Biotech advances manufacturing process for clinical trial in pancreatic cancer

PharmaCyte Biotech, a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced that advances have been completed in the manufacturing process for the clinical trial product that will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

Pear Therapeutics initiates feasibility study to treat depressive symptoms in people with multiple sclerosis

Pear Therapeutics, Inc. announced the start of a feasibility study for a prescription digital therapeutic (PDT) intended to treat depressive symptoms in people with Multiple Sclerosis (MS). Known as Pear-006, the PDT is intended to be used in combination with disease-modifying treatment.

WuXi AppTec buys clinical research services firm Pharmapace

WuXi AppTec has acquired US-based clinical research services firm, Pharmapace, for an undisclosed sum.

GSK, Innoviva’s Trelegy Ellipta meets primary endpoint in phase III asthma study

GlaxoSmithKline (GSK) and Innoviva’s respiratory drug Trelegy Ellipta has met primary endpoint in the phase III CAPTAIN (clinical study of asthma patients receiving triple therapy through a single inhaler) study.